‘Finally seen, heard': Sex workers at India's largest red-light area Sonagachi say healthcare access has improved
Once faced with discrimination and barriers to medical care, many sex workers now report improved treatment at government hospitals and clinics. 'Now we are not treated differently. I go for check-ups in government hospitals, stand in the queue like every other patient, and get treated without facing discrimination,' said Dolly, 34, a sex worker in Sonagachi.
A key factor behind this shift has been the work of the Durbar Mahila Samanwaya Committee (DMSC) — a collective run by and for sex workers that has completed 30 years of work across West Bengal. Durbar operates 51 free clinics for sex workers in the state, including health centres in Sonagachi that offer HIV and STD testing, low-cost medicines, and regular health check-ups in safe and non-judgmental spaces.
To mark its 30th anniversary, DMSC is hosting a community fair from July 12 to 15 at Rabindra Kanan Park in Kolkata, celebrating the lives and livelihood of sex workers. The event featured panel discussions with doctors from across the state, who spoke about the prevention and early detection of HIV, STDs, breast cancer and cervical cancer. Guidelines on menstrual hygiene and care during menstruation were also shared.
'Previously there was a taboo — people believed sex workers were not from our class, not like us,' said Dr Soma Dutta, a Kolkata-based gynaecologist. 'But with more education, awareness programmes, and the consistent work by DMSC, even hospitals are more inclusive now.'
'DMSC has helped us gain confidence. Earlier, doctors and nurses refused to treat us because of our profession. Now, we are treated like any other human being,' said Nila, 45. 'After all, we are human beings too, and we deserve respect.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
4 gut-friendly foods every woman should add to her diet
Dr. Saurabh Sethi recommends incorporating specific foods into your diet to enhance gut health, particularly beneficial for women's hormone balance, immunity, and mood. Leafy greens, blueberries, fermented foods like homemade yogurt and kefir, and pumpkin seeds are highlighted for their magnesium, fiber, antioxidants, probiotics, zinc, and digestive benefits. These choices support a healthy gut microbiome and overall well-being. Gut health is crucial for overall well-being. When it comes to women, it is even more crucial, as gut health is intricately tied to hormones, immunity, and mood. Keeping the gut happy and healthy is the first step towards a healthy lifestyle. But how does one keep the gut in top shape? Good diet. Dr. Saurabh Sethi, a California-based gastroenterologist, has shared a list of foods that one can add to the diet to boost gut health. Leafy greens Mums are never wrong. They have been telling us to eat greens since childhood. Well, its time to finally listen to them. Greens, especially leafy greens, are good for health. Dr. Sethi noted that magnesium and fiber are two essential nutrients for gut health. Magnesium helps to relax the intestinal muscles and aids in regular bowel movement. It also reduces cramping in women. Fiber, on the other hand, is fuel for beneficial gut bacteria. It also bulks up the stool and prevents constipation. You can add leafy greens like spinach, kale, and Swiss chard to your daily routine. They can be sautéed with other veggies or added to smoothies. Blueberries Who knew boosting gut health could be a delectable habit! Blueberries make your gut happy and healthy. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo These berries are rich in antioxidants and polyphenols, which prevent inflammation and nourish gut bacteria. The polyphenols also support brain health, by improving mood and cognitive function. You can have blueberries as a snack o, or toss them into yogurt for a creamy treat. Fermented foods Fermented foods such as yogurt, and, kefir are loaded with probiotics, which foster the healthy gut microbiome. However, it is important to go for home-made fermented foods. Because the store-bought foods are often loaded with preservatives, which kill their protective effects. Dr. Sethi also added that fermented foods such as yogurt and kefir are also good for women, as they support the vaginal microbiome and reduce the risk of infections like yeast overgrowth. Also, ensure to choose unsweetened, plain yogurt or kefir. Excessive sugar can disrupt the beneficial gut microbiome. You can add yogurts for smoothies or have it as a side during meals. 5 Seeds that can help in quick weight loss Pumpkin seeds Pumpkin seeds are a nutritious addition to your diet. They are rich in zinc and fiber, which support immune and digestive health. Zinc helps to maintain a healthy gut lining, which prevents issues like leaky gut syndrome. The fiber in pumpkin seeds, on the other hand, promotes digestion. You can add them to your breakfast, or sprinkle them on salads, blend them into smoothies, or even enjoy them roasted as a snack.
Economic Times
5 hours ago
- Economic Times
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
Dr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The company plans a significant expansion with the generic version of semaglutide across 87 countries by 2026, alongside developing 26 GLP-1 products over the next decade. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET.'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.'The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver.'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query.'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade.'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio company's India and emerging markets business grew 11% and 17% company's EBITDA margin for the first quarter stood at 26.7%.
Time of India
5 hours ago
- Time of India
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET. 'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.' Explore courses from Top Institutes in Please select course: Select a Course Category Technology Leadership Project Management Healthcare Management Data Analytics Data Science others Cybersecurity Artificial Intelligence Design Thinking Degree Product Management Public Policy Data Science MCA Finance MBA Others healthcare Operations Management PGDM CXO Digital Marketing Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo 'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query. 'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he said. Live Events The company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade. 'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Israeli. On Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% y-o-y. Israeli said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product launches. The company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% year-on-year. However, revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio acquisition. The company's India and emerging markets business grew 11% and 17% respectively. The company's EBITDA margin for the first quarter stood at 26.7%.
